Initially, the MUSE study was a multicentre randomised placebo-controlled phase IIb trial involving 305 SLE patients.10 The latter were randomised 1:1:1 based on their baseline IFN scores, disease activity and oral glucocorticoid dosage, to IV anifrolumab 300mg or 1000mg/month or placebo. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.